BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Notiretatug rezetecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Notiretatug rezetecan\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06915142-2064@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Notiretatug rezetecan: Phase 2 readout est. (NCT06915142)
DESCRIPTION:Notiretatug rezetecan\, phase 2.\nStudy: A Phase II Clinical St
 udy of HRS-7058 in Combination With Antitumor Drugs in Patients With Advan
 ced Malignant Tumour\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/notiretatug-rezetecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06915142
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819319-2064@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Notiretatug rezetecan: Phase 2 readout est. (NCT06819319)
DESCRIPTION:Notiretatug rezetecan\, phase 2.\nStudy: SHR-A2102 Combined Wit
 h Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Canc
 er\nEstimated primary completion: 31 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06819319
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05076682-2064@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Notiretatug rezetecan: Phase 2 readout est. (NCT05076682)
DESCRIPTION:Notiretatug rezetecan\, phase 2.\nStudy: Reverse Triple Negativ
 e Immune Resistant Breast Cancer\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/notiretatug-r
 ezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05076682
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059221-2064@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Notiretatug rezetecan: Phase 1/2 readout est. (NCT07059221)
DESCRIPTION:Notiretatug rezetecan\, phase 1/2.\nStudy: A Trial of SHR-A2102
  With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/
 MetastaticHead and Neck Squamous Cell Carcinoma Cancer\nEstimated primary 
 completion: March 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/notiretatug-rezetecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07059221
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547736-2064@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Notiretatug rezetecan: Phase 2 readout est. (NCT06547736)
DESCRIPTION:Notiretatug rezetecan\, phase 2.\nStudy: Exploratory Platform R
 esearch on Precision Therapy of Advanced Pancreatic Cancer\nEstimated prim
 ary completion: March 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/notiretatug-rezetecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06547736
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06433609-2064@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Notiretatug rezetecan: Phase 2 readout est. (NCT06433609)
DESCRIPTION:Notiretatug rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of ADCs Combined With Adebrelimab in HER2-negative Ad
 vanced Breast Cancer\nEstimated primary completion: March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06433609
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07414953-2064@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Notiretatug rezetecan: Phase 1 readout est. (NCT07414953)
DESCRIPTION:Notiretatug rezetecan\, phase 1\, Non-Small Cell Lung Cancer.\n
 Study: A Phase Ib Study of HS-10504 Combined Therapy in NSCLC\nEstimated p
 rimary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/notiretatug-rezetecan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07414953
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06639347-2064@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Notiretatug rezetecan: Phase 1/2 readout est. (NCT06639347)
DESCRIPTION:Notiretatug rezetecan\, phase 1/2\, Urothelial Carcinoma.\nStud
 y: A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carc
 inoma\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06639347
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418749-2064@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Notiretatug rezetecan: Phase 3 readout est. (NCT07418749)
DESCRIPTION:Notiretatug rezetecan\, phase 3\, Cervical Cancer.\nStudy: A St
 udy of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients 
 With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Re
 current or Metastatic Cervical Cancer\nEstimated primary completion: Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/notiretatug
 -rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07418749
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393542-2064@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Notiretatug rezetecan: Phase 3 readout est. (NCT07393542)
DESCRIPTION:Notiretatug rezetecan\, phase 3\, Urothelial Carcinoma.\nStudy:
  A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic U
 rothelial Carcinoma\nEstimated primary completion: 31 January 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/notiretatug-rezetecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07393542
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175220-2064@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Notiretatug rezetecan: Phase 2 readout est. (NCT07175220)
DESCRIPTION:Notiretatug rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti
 -tumor Treatments in Non-small Cell Lung Cancer Subjects\nEstimated primar
 y completion: October 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/notiretatug-rezetecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07175220
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06895928-2064@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Notiretatug rezetecan: Phase 2 readout est. (NCT06895928)
DESCRIPTION:Notiretatug rezetecan\, phase 2.\nStudy: A Trial of SHR-A2102 W
 ith Other Antitumor Therapies in Advanced Solid Tumors\nEstimated primary 
 completion: December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/notiretatug-rezetecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06895928
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06879145-2064@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Notiretatug rezetecan: Phase 2/3 readout est. (NCT06879145)
DESCRIPTION:Notiretatug rezetecan\, phase 2/3.\nStudy: Clinical Study on th
 e Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebre
 limab (SHR-1316)\nEstimated primary completion: December 2031. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06879145
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417554-2064@assetmemo.bio
DTSTAMP:20261121T005940Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Notiretatug rezetecan: Phase 1/2 readout est. (NCT06417554)
DESCRIPTION:Notiretatug rezetecan\, phase 1/2.\nStudy: A Trial of SHR-A2102
  With or Without Antitumor Therapy in Advanced Solid Tumors\nEstimated pri
 mary completion: 31 December 2031. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/notiretatug-rezetecan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06417554
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
